A cancer center cannot treat a patient on infusion-day judgment alone — it runs on a tight three-way handshake between the pharmacy that compounds the dose, the laboratory that clears the patient to receive it, and imaging that stages, plans, and monitors the disease. Where these three support services sit relative to the infusion suite, the exam clinic, and the radiation-oncology vaults is one of the most consequential planning decisions in the whole project. Good adjacencies compress the same-day visit, protect a hazardous-drug chain of custody, and keep an immunocompromised population out of crowded shared corridors; poor ones force pneumatic-tube workarounds, courier runs, long round-trips, and dose waste. This article is about the relationship and placement logic — why each service wants to be where it wants to be, and the trade-offs when it can't. The interior engineering of hazardous-drug compounding (USP <800> ventilation, room pressurization, C-PEC selection) is treated in its own Article; here it appears only as an adjacency driver.
The defining operational fact of medical oncology is the same-day, sequential visit: a patient arrives, has blood drawn, sees the provider, and — if labs and the exam clear them — receives a chemotherapy or biologic infusion compounded that morning. Each step gates the next, and the chemotherapy dose is frequently not compounded until labs return and the physician signs the order, because antineoplastic agents are dosed to body-surface-area, renal/hepatic function, and absolute neutrophil and platelet counts that can shift between cycles. A dose mixed too early for a patient who turns out to be neutropenic, dehydrated, or below platelet threshold is a wasted, expensive, hazardous-waste-generating compound.
This sequence sets the master adjacency requirement: lab result → pharmacy compounding → infusion delivery must close in a time window short enough that the patient is not stranded in the chair waiting, and short enough that an outpatient day-clinic can turn its infusion chairs more than once. The whole adjacency diagram of a cancer center is, in effect, an attempt to shrink the latency of that loop while keeping each function in a space that meets its own code envelope. When planners draw bubble diagrams for an oncology project, the first relationship they fix is usually lab draw → pharmacy → infusion, and everything else negotiates around it.
The oncology (infusion) pharmacy is the most placement-sensitive of the three services because it is simultaneously pulled toward the chairs and constrained by a containment envelope that the chairs do not share.
Why it wants to be adjacent to infusion. Hazardous, sterile, patient-specific doses are often short-stable (some reconstituted biologics and cytotoxics are stable only for hours), must be transported by hand in sealed secondary containment rather than dropped down a pneumatic tube (tubes are widely prohibited for hazardous drugs because of breakage/aerosolization risk), and frequently need re-compounding or substitution in real time when an order changes at the chairside. The closer the compounding room is to the infusion suite, the shorter the controlled hand-carry, the faster the turnaround, and the less product is lost to expiry. The strong planning target is a direct, staff-only pass-through relationship — ideally the cleanroom suite shares a wall or a short clean corridor with the infusion delivery alcove, with a dedicated pass-through window or anteroom hand-off rather than a public-corridor trek.
Why it is also a containment island. A USP <800> hazardous-drug compounding suite is a negative-pressure, externally-exhausted, anteroom-gated set of rooms with its own air-change and finish requirements — engineered to FGI Guidelines and ASHRAE 170 for the sterile-compounding suite and to USP <797>/<800> for the compounding and containment regime. That envelope cannot be casually merged with the open, comfortable, daylight-seeking infusion bay. So the pharmacy reads on the plan as a sealed block pressed against the infusion suite — adjacent for transport, isolated for containment — with the hand-off detail (pass-through window, gowning/de-gowning anteroom, spill-control staging) being the critical interface to get right.
Receiving and waste are part of the adjacency. Hazardous-drug receiving (a designated, negative- or neutral-pressure unpacking area separate from the cleanroom) and hazardous-pharmaceutical waste staging both want a back-of-house relationship to the pharmacy that does not cross patient territory. A clean planning solution gives the pharmacy a service-corridor face for delivery and RCRA/USP <800> waste pickup on one side, and the patient-facing infusion hand-off on the other — a two-faced room. When that back-of-house face is missing, deliveries and waste end up routed through clinical corridors, which is both a contamination and a regulatory exposure.
Non-hazardous and supportive compounding. Many cancer centers also run hydration, antiemetic, growth-factor, and other non-hazardous sterile preparations. These can share the sterile suite but are often handled in a separate, positive-pressure ISO buffer room from the negative-pressure hazardous room — another reason the "pharmacy" is really a small cluster of differently-pressurized rooms whose collective footprint and exhaust strategy must be reserved early.
The cancer-center laboratory adjacency splits into two very different things that planners must not conflate: the point-of-care / phlebotomy front end and the analytical laboratory back end.
The front end must be on the patient's path. Phlebotomy (blood draw) for the day's treatment-clearance labs — CBC with differential, comprehensive metabolic panel, and tumor-specific markers — has to sit at the start of the clinic flow, before the exam and before pharmacy gets the green light. The ideal is a phlebotomy/draw station immediately inside the cancer-center front, co-located with check-in/registration so the patient gives blood first and the result is already running while they wait for the provider. Some programs push a small STAT / rapid-turnaround lab (or at least a CBC analyzer and chemistry analyzer) on-site precisely to close the lab→pharmacy loop in minutes rather than tube-and-wait, because the alternative — sending specimens to a central hospital core lab — adds courier or pneumatic-tube transit and queue time that lengthens every chair turn.
The back end can be remote — and usually is. The full analytical laboratory (hematology, chemistry, microbiology, anatomic pathology, molecular/genomic, blood bank) is space-, utility-, and staff-heavy, and in a hospital-based program it almost always lives in a shared central core laboratory rather than being duplicated in oncology. The adjacency that matters there is a reliable, fast specimen-transport link — pneumatic tube and/or scheduled courier — from the cancer-center draw station to the core lab, plus a results interface back into the EHR and pharmacy order system. The planning decision is essentially make-or-buy on proximity: how much analytical capability to localize on-site (faster loop, duplicated cost) versus how much to leave central (cheaper, but transport-latency-bound). Freestanding cancer centers and ambulatory infusion centers tend to localize more because they have no central core lab to lean on.
Blood bank and transfusion. Oncology patients frequently need blood-product transfusion (packed cells, platelets) on the same infusion visit. That creates an adjacency to transfusion services / blood bank — either an on-site dispensing refrigerator and crossmatch capability, or a tight, validated cold-chain link to the hospital blood bank. Transfusion typically happens in the infusion chairs, so the blood-product delivery path joins the same lab→infusion logistics the chemotherapy doses use, and benefits from the same short, controlled route.
Pathology and the diagnostic loop. Anatomic and molecular pathology sit further upstream in the cancer journey (biopsy diagnosis, staging, biomarker testing that drives therapy selection) rather than in the day-of-treatment loop, so they rarely demand physical adjacency to infusion. Their adjacency is to the procedure/biopsy spaces and imaging that generate specimens, and to a specimen-transport path. Planners should map this loop, but it competes far less for prime cancer-center real estate than phlebotomy does.
"Imaging" in oncology is not one adjacency request; it is at least three, with very different placement logic.
Diagnostic / restaging imaging (CT, MRI, PET-CT). Cross-sectional imaging stages disease at diagnosis and re-stages it to judge treatment response between cycles. Patients on active therapy cycle through these scanners repeatedly, so a cancer center benefits from convenient access to CT, MRI, and especially PET-CT — but these are heavy, shielded, utility-intense rooms (MRI needs magnetic shielding, an RF cage, quench venting, and the zoned 5-gauss/screening discipline; PET-CT needs radiation shielding and a controlled radiopharmaceutical hot-lab/uptake-room workflow). Because of that weight and cost, diagnostic imaging is frequently a shared hospital resource one trip away rather than embedded in the oncology suite. The realistic target is easy wayfinding and a short internal route to the imaging department, not co-location of the scanners themselves — unless the program is large enough (or freestanding enough) to justify a dedicated cancer-imaging suite.
PET and nuclear-medicine radiopharmaceuticals — a special adjacency. PET-CT and theranostic/radiopharmaceutical therapy bring short-half-life, externally-supplied radioisotopes and an on-site hot lab / radiopharmacy with its own shielding, hot-lab ventilation, decay/storage, and radioactive-waste handling, governed by NRC (and Agreement-State) materials licensing and the facility radiation-safety program. The adjacency logic here is dose-delivery-timing (isotopes decay fast, so the hot lab wants to be near the scanner and on a back-of-house delivery dock) and radiation-protection zoning (uptake rooms where dosed patients wait must be shielded and segregated). This is engineered alongside — but distinct from — the radiation-oncology shielding problem, and is mostly out of the oncology pharmacy's hazardous-drug envelope.